NVNO vs DBVT vs ALKS vs VNRX vs PRGO

For growth investors, VolitionRx Limited (VNRX) is the stronger pick with 40.

0% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 5x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, enVVeno Medical Corporation (NVNO) delivered a total return of +87.

9%, compared to -96. 3% for VolitionRx Limited (VNRX). Over 10 years, the gap is even starker: ALKS returned -12. 0% versus VNRX's -96. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), VolitionRx Limited (VNRX) is the lower-risk stock at 0.

28β versus enVVeno Medical Corporation's 2. 02β — meaning NVNO is approximately 632% more volatile than VNRX relative to the S&P 500. On balance sheet safety, enVVeno Medical Corporation (NVNO) carries a lower debt/equity ratio of 3% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), VolitionRx Limited (VNRX) is pulling ahead at 40.

0% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: enVVeno Medical Corporation grew EPS 97. 9% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, VNRX leads at 78. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -1352. 2% for VolitionRx Limited — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -1228. 6% for VNRX. At the gross margin level — before operating expenses — VNRX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PRGO: 209.

1% to $36. 20.

In this comparison, PRGO (9.

8% yield) pays a dividend. NVNO, DBVT, ALKS, VNRX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, VolitionRx Limited (VNRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

28)). enVVeno Medical Corporation (NVNO) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VNRX: -96. 5%, NVNO: -92. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NVNO is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; VNRX is a small-cap high-growth stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while NVNO, DBVT, ALKS, VNRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.